Pregnancy: a risk factor for Budd-Chiari syndrome?
- questionable contraception. Martin, Adam // Health (Time Inc. Health);Sep2003, Vol. 17 Issue 7, p74
Discusses the results of a survey of French women who got pregnant unintentionally. Percentage of the respondents who were using contraceptives; Birth control methods used; Duration of high-dose oral contraceptives.
- Long-term OC use may increase miscarriage risk. // Reactions Weekly;8/20/2005, Issue 1065, p3
Reports on the link between long-term use of oral contraceptives (OC) and increased risk of miscarriage according to the results of a case-control study. Odds ratio for miscarriage for patients who had taken OC for twenty four months prior to pregnancy; Ages of women susceptible to miscarriage.
- Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Kemmeren, Jeanet M; Algra, Ale; Grobbee, Diederick E // BMJ: British Medical Journal (International Edition);7/21/2001, Vol. 323 Issue 7305, Special section p1
Results: The overall adjusted odds ratio for third versus second generation oral contraceptives was 1.7 (95% confidence interval 1.4 to 2.0; seven studies). Similar risks were found when oral contraceptives containing desogestrel or gestodene were compared with those containing levonorgestrel....
- Male sex, first idiopathic deep venous thrombosis, and oral contraception were risk factors for recurrent venous thrombotic events. Christiansen, S. C.; Cannegieter, S. C.; Koster, T. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p59
The article reports focuses on a study on the contribution of male gender, first idiopathic deep venous thrombosis and oral contraception on the occurrence of recurrent venous thrombotic events. Prothrombotic abnormalities however did not appear to play an important role. The study was conducted...
- HORMONAL CONTRACEPTION AND THROMBOSIS. Costescu, Dustin J.; Waddington, Ashley; Rosendaal, Frits R.; Helmerhorst, Frans M. // BMJ: British Medical Journal;4/20/2013, Vol. 346 Issue 7904, p25
A letter to the editor is presented in response to the article ``Is an EMA review on hormonal contraception and thrombosis needed?'' by Helmerhorst and Rosendaal in the March 7, 2013 issue.
- Meta-analysis of thrombosis risk with oral contraceptives. // Reactions Weekly;9/28/2013, Issue 1471, p4
The article focuses on the meta-analysis of thrombosis risk associated with oral contraceptives and reports that the risk of venous thrombosis was increased in individuals taking oral contraceptives as compared to non-users.
- etonogestrel. // Royal Society of Medicine: Medicines;2002, p237
This article focuses on progestogen etonogestrel. It is used as an oral contraceptive in the form of implant.
- etynodiol diacetate. // Royal Society of Medicine: Medicines;2002, p237
This article presents information on the progestogen etynodiol diacetate. It is used as a constituent of the progestogen-only type oral contraceptive pills. It is administered orally.
- Marvelon. // Royal Society of Medicine: Medicines;2002, p347
This article presents information on Marvelon, a proprietary, prescription-only compound preparation than can be used as oral contraceptives of the COC type that combines an estrogen and progesterone, in this case ethinylestradiol and desogestrel. It is available as tablets.